Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 68

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 68
---
, Gilead owned approximately 29.7% of our common stock.

For more information about our collaboration with Gilead, including the Gilead Collaboration Agreement, Purchase Agreement and Investor Rights Agreement, please refer to the information disclosed in our Annual Report under “License and Collaborations—Gilead Collaboration.”

#### Employment of Relatives of Executive Officer
A son of Terry Rosen, Ph.D., our Chief Executive Officer and member of the Board, has been employed by us since February 2016, currently in the capacity of Research Fellow. In 2024, he earned approximately $247,000 in annual salary and other cash compensation. In 2024, he was also granted (i) an option to purchase 1,388 shares of common stock with an exercise price of $15.44 per share and (ii) 2,112 restricted stock units. The grant date fair value of the option award and restricted stock unit award, computed in accordance with FASB ASC Topic 718 were $14,981 and $32,609, respectively. He also received other benefits consistent with other employees serving in the same capacity.

Another son of Dr. Rosen has been employed by us since November 2020, currently in the capacity of Senior Scientist. In 2024, he earned approximately $206,473 in annual salary and other cash compensation. In 2024, he was also granted (i) an option to purchase 800 shares of common stock with an exercise price of $15.44 per share and (ii) 1,200 restricted stock units. The grant date fair value of the option award and restricted stock unit award, computed in accordance with FASB ASC Topic 718, were $8,635 and $18,528, respectively. He also received other benefits consistent with other employees serving in the same capacity.

A daughter-in-law of Dr. Rosen has been employed by us since March 2024 as a Senior Bioinformatics Scientist, in our bioinformatics department. In 2024, she earned approximately 136,383 in annual salary and other cash compensation. In connection with her hiring, she was granted an option to purchase 3,200 shares of common stock with an exercise price of $16.97 per share and 1,600 restricted stock units. The grant date fair value of the option award and restricted stock unit award, computed in accordance with FASB ASC Topic 718 were approximately $37,997 and $27,152, respectively.

<div align='center